DRG Market Assessment reports

Treatment of CSU and CIndU is dominated by oral medications, including approved therapies such as first- and second-generation antihistamines and a range of off-label options (e.g.,…

Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…

Agents for treating major depressive disorder (MDD) span multiple drug classes; while selective serotonin reuptake inhibitors (SSRIs) and serotonin / norepinephrine reuptake inhibitors (SNRIs) are…

With a drug-treated population of more than 3.3 million in the United States, France, Germany, and the United Kingdom, the moderate to severe psoriasis therapy market has been a lucrative space for…

Clarivate Epidemiology’s coverage of obsessive-compulsive disorder (OCD) comprises epidemiological estimates of key patient populations in the European countries (Austria, Belgium, Czech Republic…

Clarivate Epidemiology’s coverage of obsessive-compulsive disorder (OCD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Clarivate Epidemiology’s coverage of irritable bowel syndrome comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report prevalence of irritable bowel…

Clarivate Epidemiology’s coverage of irritable bowel syndrome comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report prevalence of irritable bowel…

Clarivate Epidemiology’s coverage of irritable bowel syndrome (IBS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of IBS for…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key irritable bowel syndrome patient populations, covering 171…

Clarivate Epidemiology’s coverage of cystic fibrosis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence and the…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key cystic fibrosis patient populations covering 171 countries and more…